{"id":"oros-hydromorphone-hcl-oxycontin","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"constipation"},{"rate":"10-20%","effect":"nausea"},{"rate":"5-15%","effect":"vomiting"},{"rate":"5-10%","effect":"dizziness"},{"rate":"5-10%","effect":"headache"}]},"_chembl":{"chemblId":"CHEMBL1237055","moleculeType":"Small molecule","molecularWeight":"321.80"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This binding causes a decrease in the transmission of pain signals to the brain, resulting in pain relief. OROS technology allows for a sustained release of hydromorphone, providing a consistent level of pain relief over an extended period.","oneSentence":"OROS hydromorphone HCL is a long-acting opioid analgesic that works by binding to opioid receptors in the brain, spinal cord, and other areas of the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:52.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time"}]},"trialDetails":[{"nctId":"NCT00261495","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2006-03","conditions":"Pain","enrollment":504},{"nctId":"NCT01205126","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-12","conditions":"Pain","enrollment":260},{"nctId":"NCT01648699","phase":"PHASE4","title":"Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain","status":"TERMINATED","sponsor":"Janssen Pharmaceutica","startDate":"2010-04","conditions":"Pain","enrollment":20},{"nctId":"NCT00399048","phase":"PHASE3","title":"An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OROS hydromorphone HCL ; OxyContin","genericName":"OROS hydromorphone HCL ; OxyContin","companyName":"Alza Corporation, DE, USA","companyId":"alza-corporation-de-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OROS hydromorphone HCL is a long-acting opioid analgesic that works by binding to opioid receptors in the brain, spinal cord, and other areas of the body. Used for Management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}